Can Depakote (valproic acid) cause an increased pulse (tachycardia)?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: November 18, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Can Depakote Increase Pulse?

Yes, Depakote (valproic acid) can cause tachycardia (increased pulse), though this is not a common adverse effect at therapeutic doses.

Evidence from FDA Drug Labeling

The official FDA labeling for Depakote explicitly lists tachycardia as a cardiovascular adverse reaction, occurring in greater than 1% but less than 5% of patients treated with valproate in controlled trials of complex partial seizures 1. The drug label also documents palpitation and hypertension in the same frequency range, indicating that cardiovascular effects including increased heart rate do occur with this medication.

Context: When Does This Occur?

The relationship between Depakote and increased pulse appears most prominent in two clinical scenarios:

1. Overdose/Intoxication Settings

Tachycardia is a well-documented feature of valproic acid toxicity:

  • A case report of severe VPA intoxication (plasma level 1,150 mg/L) documented atrial tachycardia as a presenting feature 2
  • A pediatric overdose case (6,000 mg ingestion) demonstrated tachycardia during the acute toxic phase 3
  • A comparative cohort study found tachycardia occurred in 5 out of 15 patients with valproate-only poisoning 4

2. Therapeutic Dosing

At standard therapeutic doses, tachycardia occurs but is relatively uncommon (1-5% incidence) 1. Importantly, one study specifically evaluating rapid IV infusion of valproate sodium (up to 6 mg/kg/minute) found no clinically significant negative effects on pulse rate 5, suggesting that the tachycardia seen in clinical practice may be related to other factors or individual patient susceptibility.

Clinical Implications

Monitor for tachycardia particularly in:

  • Patients receiving high doses or experiencing toxicity (check valproate levels if tachycardia develops)
  • Overdose situations where tachycardia may accompany other serious effects (CNS depression, metabolic acidosis, thrombocytopenia)
  • Patients with pre-existing cardiac conditions

Important caveat: When tachycardia occurs in patients on Depakote who are also taking other medications (especially other antiepileptic drugs), it may be difficult to determine whether valproate alone is responsible 1. One case report suggested valproate may have precipitated neuroleptic malignant syndrome (which includes tachycardia) in a patient on antipsychotics 6.

Bottom Line

While tachycardia is a recognized adverse effect of Depakote per FDA labeling, it is relatively uncommon at therapeutic doses (1-5% incidence). It becomes more prominent in overdose situations. If a patient on Depakote develops new-onset tachycardia, check valproate levels, review concomitant medications, and evaluate for other causes of tachycardia before attributing it solely to valproate.

Related Questions

Can Depakote (valproic acid) be given orally and valproic acid intravenously on the same day, and what are the appropriate dosing guidelines?
What is the recommended management for a patient experiencing a burning sensation on the face while taking Depakote (valproic acid)?
Can Depakine (valproic acid) cause dizziness or vertigo?
What is the recommended starting dose and titration schedule for valproic acid (Depakote) in elderly patients?
For a patient on Depakote (valproic acid), what laboratory tests should be ordered for follow‑up?
Can a patient with a penicillin allergy be prescribed oral cephalexin 500 mg three times daily for a urinary tract infection for 10 days?
What are the indications, dosing regimens, contraindications, and adverse effects of alvimopan and methyl‑naltrexone (extended‑release naltrexone)?
Can you define and explain data types, food hygiene and safety practices, adolescent health services, the agency overseeing GIFTS, types of pollution and how deforestation causes land pollution, sensitivity, specificity, and positive predictive value, the CHPS program and its leadership, Ghana's health system structure, occupational health hazards and their health implications, urbanization's social and health problems, how to conduct a cohort study, the relationship between poverty and health, and common measures of fertility?
Which tumors secrete erythropoietin?
What are the differential diagnoses and pertinent questions to ask for a patient presenting with loss of visual field in the left eye?
Can you compare demographic transition theory with logistic growth and define sensitivity, specificity, and positive predictive value, list antenatal non‑communicable disease services, WHO‑recommended iron‑folic acid supplementation duration, investigations at the antenatal booking visit, signs of rat infestation, the meaning and staff of Community‑Based Health Planning Services (CHPS), benefits of school feeding programs, social implications of teenage pregnancy, diseases excluded from NHIS pre‑employment assessment, components of periodic workplace health assessments, health and economic impacts of festivals, and the services a community medical officer should provide (antenatal care, immunizations, family planning, cohort study)?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.